Core Insights - Shenzhen Haichuang Biotechnology Co., Ltd., the parent company of the immune anti-aging brand Haipuno, completed a multi-million RMB Series A financing round on October 17, 2023, led by Sanze Venture Capital, with Guangyuan Capital serving as the exclusive financial advisor [1][2] - The funds from this financing round will primarily be used for new product development, brand building, and team expansion [1] - Haichuang Biotechnology has a strong background in technological innovation, having been recognized as a "seed unicorn enterprise" at the China (Shenzhen) Unicorn Enterprise Conference in July 2025 [1] Financing History - The company has undergone multiple financing rounds, including: - Series A on October 17, 2023, amounting to several tens of millions RMB [2] - Pre-A+ round on February 21, 2023, also amounting to several tens of millions RMB [2] - Pre-A round on April 10, 2022, with nearly ten million RMB raised [2] - The increasing capital interest reflects a preference for "research-driven, efficacy-oriented" brands in the competitive cosmetics industry [2] Company Background - Founded in 2020 by Professor Liu Zhigang and Dr. Wang Zhiyao, Haichuang Biotechnology leverages over 30 years of immunology research from Shenzhen University [4] - The company focuses on developing functional skincare products, probiotics, and bioactive raw materials, aiming for a comprehensive layout across "cosmetics, food, medicine, and devices" [4] - The R&D team has published over 300 academic papers related to immunology, with more than 60% holding doctoral degrees [4] Product Performance - The Haipuno skincare series achieved total sales of 50 million RMB from 2023 to March 2024, with a stable repurchase rate of over 60% [5] - The company’s proprietary ingredient HEPRO-6A® has won multiple innovation awards and is central to its product offerings [4][7] Market Strategy - The recent financing indicates strong market recognition and effective sales conversion driven by robust scientific research [6] - The company is set to upgrade its proprietary ingredient to HEPRO-6A PRO in 2024, enhancing its efficacy [7] - Haichuang Biotechnology is also developing functional probiotic products and medical devices for specific skin conditions, indicating a broadening of its product portfolio [9] Industry Trends - The financing reflects a broader trend in the cosmetics industry towards technology-driven and comprehensive product offerings, as consumer demand for efficacy increases [7] - The company's strategy of integrating research, product development, and market engagement serves as a model for other technology-oriented enterprises in the sector [7]